首页> 外文OA文献 >Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

【2h】

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

机译：铂难治性非小细胞肺癌（NSCLC）患者的表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）吉非替尼和环氧化酶2（COX-2）抑制剂塞来昔布的II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Gadgeel Shirish M.; Ruckdeschel John C.; Heath Elisabeth I.; Heilbrun Lance K.; Venkatramanamoorthy Raghu; Wozniak Antoinette;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. [J] . Ramalingam S, Forster J, Naret C, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第3期

机译：在难治性非小细胞肺癌（NSCLC）患者中，西妥昔单抗（IgG1单克隆抗体）和吉非替尼（酪氨酸激酶抑制剂）对表皮生长因子受体的双重抑制：I期研究。
2. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第2016期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
3. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第4期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
6. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [O] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, 2007

机译：卡博替尼+厄洛替尼在晚期表皮生长因子受体（EGFR）-突变型非小细胞肺癌进展性疾病中进行表皮生长因子受体酪氨酸激酶抑制剂治疗的II期试验：加利福尼亚癌症协会II期试验（NCI 9303）
7. Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study [O] . Ramalingam Suresh, Forster Judy, Naret Cynthia, 2008

机译：难治性非小细胞肺癌（NSCLC）患者用IgG1单克隆抗体西妥昔单抗和酪氨酸激酶抑制剂吉非替尼双重抑制表皮生长因子受体：I期研究

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

著录项

引文网络

相似文献

相关主题

期刊订阅